449 related articles for article (PubMed ID: 28434181)
1. Management Options for Biochemically Recurrent Prostate Cancer.
Fakhrejahani F; Madan RA; Dahut WL
Curr Treat Options Oncol; 2017 May; 18(5):26. PubMed ID: 28434181
[TBL] [Abstract][Full Text] [Related]
2. Upfront androgen deprivation therapy with salvage radiation may improve biochemical outcomes in prostate cancer patients with post-prostatectomy rising PSA.
Jang JW; Hwang WT; Guzzo TJ; Wein AJ; Haas NB; Both S; Vapiwala N
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1493-9. PubMed ID: 22401922
[TBL] [Abstract][Full Text] [Related]
3. Treatment failure and clinical progression after salvage therapy in men with biochemical recurrence after radical prostatectomy: radiotherapy vs androgen deprivation.
Song C; Kim YS; Hong JH; Kim CS; Ahn H
BJU Int; 2010 Jul; 106(2):188-93. PubMed ID: 20002666
[TBL] [Abstract][Full Text] [Related]
4. Management of Biochemical Recurrence after Primary Curative Treatment for Prostate Cancer: A Review.
Artibani W; Porcaro AB; De Marco V; Cerruto MA; Siracusano S
Urol Int; 2018; 100(3):251-262. PubMed ID: 29161715
[TBL] [Abstract][Full Text] [Related]
5. Current controversies in the management of biochemical failure in prostate cancer.
Bruce JY; Lang JM; McNeel DG; Liu G
Clin Adv Hematol Oncol; 2012 Nov; 10(11):716-22. PubMed ID: 23271258
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcomes of two ablation techniques for treatment of radio-recurrent prostate cancer.
Nair SM; Peters M; Kurver P; Lavi A; Verhoeff JJC; van der Voort van Zyp JRN; van Son MJ; Chin JL
Prostate Cancer Prostatic Dis; 2021 Mar; 24(1):186-192. PubMed ID: 32814843
[TBL] [Abstract][Full Text] [Related]
7. Use of androgen deprivation therapy as salvage treatment after primary therapy for clinically localized prostate cancer.
Fu AZ; Tsai HT; Haque R; Ulcickas Yood M; Van Den Eeden SK; Cassidy-Bushrow AE; Zhou Y; Keating NL; Smith MR; Aaronson DS; Potosky AL
World J Urol; 2016 Dec; 34(12):1611-1619. PubMed ID: 27084777
[TBL] [Abstract][Full Text] [Related]
8. Evaluation and management of the man who has failed primary curative therapy for prostate cancer.
Ornstein DK; Oh J; Herschman JD; Andriole GL
Urol Clin North Am; 1998 Nov; 25(4):591-601. PubMed ID: 10026768
[TBL] [Abstract][Full Text] [Related]
9. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
[TBL] [Abstract][Full Text] [Related]
10. Management of prostate cancer recurrence after definitive radiation therapy.
Boukaram C; Hannoun-Levi JM
Cancer Treat Rev; 2010 Apr; 36(2):91-100. PubMed ID: 20100637
[TBL] [Abstract][Full Text] [Related]
11. Avoidance of androgen deprivation therapy in radiorecurrent prostate cancer as a clinically meaningful endpoint for salvage cryoablation.
Ginsburg KB; Elshafei A; Yu C; Jones JS; Cher ML
Prostate; 2017 Oct; 77(14):1446-1450. PubMed ID: 28856702
[TBL] [Abstract][Full Text] [Related]
12. Salvage reirradiation for locoregional failure after radiation therapy for prostate cancer: who, when, where and how?
Créhange G; Roach M; Martin E; Cormier L; Peiffert D; Cochet A; Chapet O; Supiot S; Cosset JM; Bolla M; Chung HT
Cancer Radiother; 2014 Oct; 18(5-6):524-34. PubMed ID: 25192626
[TBL] [Abstract][Full Text] [Related]
13. Biochemical recurrence in patients with prostate cancer after primary definitive therapy: treatment based on risk stratification.
Shore ND; Moul JW; Pienta KJ; Czernin J; King MT; Freedland SJ
Prostate Cancer Prostatic Dis; 2024 Jun; 27(2):192-201. PubMed ID: 37679602
[TBL] [Abstract][Full Text] [Related]
14. Management of biochemically recurrent prostate cancer following local therapy.
Kolodziej M
Am J Manag Care; 2014 Dec; 20(12 Suppl):S273-81. PubMed ID: 25734963
[TBL] [Abstract][Full Text] [Related]
15. Differential Risk of Castration Resistance After Initial Radical Prostatectomy or Radiotherapy for Prostate Cancer.
Obata H; Shiota M; Akitake N; Takeuchi A; Kashiwagi E; Dejima T; Kiyoshima K; Inokuchi J; Tatsugami K; Eto M
Anticancer Res; 2017 Oct; 37(10):5631-5637. PubMed ID: 28982880
[TBL] [Abstract][Full Text] [Related]
16. Duration of Androgen Deprivation Therapy Influences Outcomes for Patients Receiving Radiation Therapy Following Radical Prostatectomy.
Jackson WC; Schipper MJ; Johnson SB; Foster C; Li D; Sandler HM; Palapattu GS; Hamstra DA; Feng FY
Eur Urol; 2016 Jan; 69(1):50-7. PubMed ID: 26004800
[TBL] [Abstract][Full Text] [Related]
17. Robotic radical prostatectomy as the initial step in multimodal therapy for men with high-risk localised prostate cancer: initial experience of 160 men.
Connolly SS; Cathcart PJ; Gilmore P; Kerger M; Crowe H; Peters JS; Murphy DG; Costello AJ
BJU Int; 2012 Mar; 109(5):752-9. PubMed ID: 21992472
[TBL] [Abstract][Full Text] [Related]
18. Best Approaches and Updates for Prostate Cancer Biochemical Recurrence.
Simon NI; Parker C; Hope TA; Paller CJ
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-8. PubMed ID: 35503984
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancer.
Taplin ME; Xie W; Bubley GJ; Ernstoff MS; Walsh W; Morganstern DE; Regan MM
J Clin Oncol; 2006 Dec; 24(34):5408-13. PubMed ID: 17135641
[TBL] [Abstract][Full Text] [Related]
20. [Adjuvant vs. salvage radiotherapy after radical prostatectomy].
Bartkowiak D; Schrader AJ; Wiegel T
Aktuelle Urol; 2015 Jan; 46(1):52-8. PubMed ID: 25658231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
